Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Sells $41,122.97 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Joshua B. Cohen sold 11,851 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $3.47, for a total transaction of $41,122.97. Following the completion of the sale, the chief executive officer now directly owns 3,201,247 shares in the company, valued at approximately $11,108,327.09. The trade was a 0.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Amylyx Pharmaceuticals Trading Up 1.9 %

Shares of NASDAQ AMLX traded up $0.07 during midday trading on Wednesday, reaching $3.69. The company’s stock had a trading volume of 1,581,960 shares, compared to its average volume of 986,350. The stock has a 50 day simple moving average of $4.07 and a 200-day simple moving average of $3.66. The stock has a market capitalization of $252.95 million, a price-to-earnings ratio of -0.97 and a beta of -0.54. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $19.95.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Bank of America raised Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $4.20 to $10.00 in a report on Wednesday, October 23rd. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a report on Thursday, December 5th. Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Robert W. Baird raised shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $3.00 to $11.00 in a report on Monday, November 18th. Finally, Leerink Partners set a $4.00 target price on shares of Amylyx Pharmaceuticals and gave the stock a “market perform” rating in a research note on Friday, October 18th. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Blue Trust Inc. lifted its position in shares of Amylyx Pharmaceuticals by 232.1% in the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after buying an additional 4,883 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Amylyx Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock worth $42,000 after purchasing an additional 5,104 shares during the last quarter. Algert Global LLC bought a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at $47,000. Y Intercept Hong Kong Ltd bought a new position in Amylyx Pharmaceuticals during the 4th quarter worth $56,000. Finally, Barclays PLC lifted its holdings in shares of Amylyx Pharmaceuticals by 91.1% during the third quarter. Barclays PLC now owns 84,572 shares of the company’s stock worth $274,000 after buying an additional 40,319 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.